Tickets for Christopher Nolan's The Odyssey on sale a year in advance for IMAX 70mm screenings
On Wednesday, IMAX announced that tickets for the first IMAX 70mm screenings were going on sale. The tickets are for showings on July 16-19, 2026.
The Bay Area has two theaters where tickets are on sale: AMC Metreon 16 in San Francisco and Regal Hacienda Crossings in Dublin. The showtimes are at 2 p.m. on July 16, 2026, and 7 p.m. July 17-19, 2026, for both theaters.
As of Wednesday night, only the front two rows had seats remaining for the Thursday showing at the Metreon. The Regal Hacienda Crossing had about three rows left. Seats for the other showings were also being bought up.
Charlize Theron, Anne Hathaway, Jon Bernthal, Matt Damon, Tom Holland, Zendaya and Robert Pattinson are among the cast in Nolan's film.
IMAX listed all the US locations where advanced tickets will be sold for the IMAX 70mm screenings.
Phoenix, AZ - Harkins Arizona Mills
Fort Lauderdale, FL - AutoNation IMAX, Museum of Discovery & Science
Atlanta, GA - Regal Mall of Georgia
Indianapolis, IN - IMAX Theatre at Indiana State Museum
Grand Rapids, MI - Celebration Cinema GR North
New York, NY - AMC Lincoln Square 13
Philadelphia, PA - Regal UA King of Prussia
Nashville, TN - Regal Opry Mills
Dallas, TX - Cinemark Dallas XD & IMAX
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Sam Rockwell tried to induce 'nervous breakdown' for scenes in 'Galaxy Quest': 'People were like, what are you doing?'
The actor referenced Gene Wilder's performance in "The Producers" as a "perfect example" of what he was trying to do. When Sam Rockwell gets a role, he's all in, dancing or whatever needs to be done. But when asked about the "most ridiculous role" he's ever committed to, there's a clear winner: Guy Fleegman, whom he played in Galaxy Quest, the 1999 movie about the cast of a former sci-fi TV series having to assume their roles in real life in order to save the universe. "Well, I think Galaxy Quest comes to mind, as far as taking it very seriously," Rockwell said of the sci-fi parody on Thursday's episode of Hot Ones. "I was walking around, [having] a lot of coffee, getting really hyped up and trying to have a nervous breakdown on camera, so that people would laugh at it, which is totally ridiculous. People were like, 'What are you doing, man? It's a comedy.' But, you know, you have to really break down or it's not funny." He pointed to Gene Wilder's performance as Leo Bloom in Mel Brooks' iconic 1967 movie The Producers as proof. Wilder, who died in 2016, is "a perfect example of that," Rockwell said. "He has a real anxiety attack, and it's hilarious." Wilder was nominated for an Oscar in the category of Best Supporting Actor for his work in the iconic film, although it's unclear how much of it was acting and how much was at least inspired by real life. The veteran of movies such as Willy Wonka & the Chocolate Factory and Young Frankenstein told Time in 1970 that he'd always had "a reservoir of hysteria," although he'd grown out of it. As for Rockwell, he's previously described his transformation for the spoof that he costarred in with Tim Allen, Sigourney Weaver, and the late Alan Rickman in a similar way. "You have to play that for real!" he told HuffPost in July 2013. "I'm really crying in the spaceship when I'm freaking out."He also said then that he'd done "full emotional preparation." "I had had four cups of coffee, and I was doing it as if it was a drama for me," Rockwell explained. "Knowing that the outcome is going to be a funny outcome, that people will be laughing at my tragedy. I was pacing, and I think Bill Paxton did the same thing in Aliens — knowing he's the funny guy, but he's got to be freaked out. He has to be legitimately scared — and that's what makes it funny. That's what great farce is: raising the stakes." Watch Rockwell's full Hot Ones conversation above. Read the original article on Entertainment Weekly
Yahoo
28 minutes ago
- Yahoo
UPDATED: Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology
Company to Pursue Technologies to Improve Brain Function, Muscle Strength, Bone Health, and Other Longevity Indicators NEW YORK, July 25, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) (the "Company" or "Klotho") announced that it is evaluating the acquisition of several complementary technologies aimed at supporting healthy brain function, organ health, and longevity. In addition to its core programs targeting brain aging and neurodegenerative diseases such as ALS, Alzheimer's, and Parkinson's, the Company is now seeking to expand into adjacent technologies that complement its proprietary anti-aging Klotho platform. The goal is to slow biological aging and reduce the burden of age-related diseases—ultimately promoting a longer, healthier life. "As announced previously, we've begun manufacturing and development of KLTO-101 and KLTO-202," said Klotho CEO Dr. Joseph Sinkule. "We're also exploring other treatments that could support healthy aging and extend human longevity." The human Klotho gene is strongly linked to aging and longevity. Klotho levels decline with age, contributing to age-related disorders such as cardiometabolic disease, neurodegeneration, cancer, sarcopenia (muscle wasting), osteoporosis, and general fatigue. Silencing of the Klotho gene has been shown to accelerate multi-organ deterioration. "The Klotho gene is what we call a master gene," stated Shalom Hirschman, M.D., world-renowned physician and senior consultant to the Company. "The Klotho gene has pleotropic actions modulating many critical cellular pathways including insulin resistance, insulin-like growth factor-1, FOXO3 transcription factors, and Wnt signaling pathways leading to the reduction of inflammatory and mitochondrial oxidative stresses and other cell-damaging mechanisms that can be prevented by two alpha-Klotho protein isoforms – soluble Klotho and secreted-Klotho." "We're assembling a team of scientists, clinicians, and business leaders focused on identifying key longevity indicators," said Jeffrey LeBlanc, Klotho CFO. "This includes evaluating genes and proteins such as alpha-Klotho, beta-Klotho, FOXO3, anti-myostatin, and their isoforms." Dr. Sinkule added, "If people don't die of cancer or trauma, they often succumb to age-related diseases of the brain, heart, kidneys, liver, bone, or muscle. Our mission is to identify and develop complementary assets to delay these outcomes through targeted research and intervention." About Klotho Neurosciences, Inc. Klotho Neurosciences, Inc. (NASDAQ: KLTO), is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti-aging" human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's, and Parkinson's disease. The company's current portfolio consists of its proprietary cell and gene therapy programs using DNA and RNA as therapeutics and genomics-based diagnostic assays. The company is managed by a team of individuals and advisors who are highly experienced in biopharmaceutical product development and commercialization. Investor Contact and Corporate Communications - Jeffrey LeBlanc, CFO, ir@ Website: Forward-Looking Statements: This press release contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Without limiting the generality of the foregoing, the forward-looking statements in this press release include descriptions of the Company's future commercial operations. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, such as the Company's inability to implement its business plans, identify and realize additional opportunities, or meet or exceed its financial projections and changes in the regulatory or competitive environment in which the Company operates. You should carefully consider the foregoing factors and the other risks and uncertainties described in the documents filed or to be filed by the Company with the U.S. Securities and Exchange Commission (the "SEC") from time to time, which could cause actual events and results to differ materially from those contained in the forward-looking statements. All information provided herein is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law. View original content to download multimedia: SOURCE Klotho Neurosciences, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28 minutes ago
- Yahoo
Larry Ellison to Hold 35.5% of Family's Voting Rights in New Paramount, National Amusements After Skydance Merger Closes
Upon closing of Paramount Global and Skydance Media's $8 billion merger, Oracle co-founder and chairman Larry Ellison will hold a minority voting interest of approximately 35.5% in the combined company. When Skydance first submitted its broadcast license transfer application to the FCC in September, the initial filing stated that the Skydance investor consortium would hold 100% of the equity and voting interests in National Amusements Inc., the holding company for Paramount's controlling stake. More from TheWrap Larry Ellison to Hold 35.5% of Family's Voting Rights in New Paramount, National Amusements After Skydance Merger Closes Paramount-Skydance Merger Expected to Close Aug. 7 As FCC Clears Paramount-Skydance Deal, All Eyes Are on Rebuilding the Media Giant As Skydance-Paramount Merger Closes, the 'South Park' Trump Takedown Shows the Fight Is On | Analysis Pinnacle Media, a group of three ventures formed 'as special-purpose vehicles to hold the Ellison family's interest in NAI and Paramount,' was set to control approximately 77.5% of such interests, while RedBird Capital Partners was expected to hold the remaining approximately 22.5%. The move signaled that the elder Ellison was poised to have a large role in New Paramount. But that was later amended in October, with Skydance stating that David Ellison would control 100% of the family's voting interest as its 'sole manager.' Now, according to the final order released by the Federal Communications Commission on Thursday, another amendment was made to Skydance's application on July 16, which states that the younger Ellison will grant Sayonara LLC, which is controlled by the elder Ellison through a revocable trust, a voting interest equal to approximately 35.5%. Meanwhile, Pinnacle Media will grant the younger Ellison 64.5% of its respective voting interest in NAI. In accordance with the voting percentages, David Ellison and Sayonara will have the right to designate the Ellison family directors of NAI and New Paramount. The amendment notes that Sayonara will not have any 'veto rights, or any special or outsized voting rights,' in NAI or New Paramount as a result of the minority voting interest. It added that the changes were being undertaken for 'the sake of efficiency and cost savings at New Paramount.' Under the two-step deal, Skydance is set to acquire controlling shareholder Shari Redstone's holding company National Amusements, which controls 77.4% of the Paramount Class A common stock outstanding and approximately 9.5% of the overall equity of the company, before merging with the Hollywood studio. The deal provides $2.4 billion for Redstone, $4.5 billion to non-NAI Paramount shareholders and an additional $1.5 billion in new capital to help pay down debt and recapitalize the company's balance sheet. Larry Ellison is providing $6 billion in financing for the deal, while the remainder will come from RedBird. Skydance's consortium of investors will control 70% of shares outstanding. The combined company will have an enterprise value of $28 billion, while Skydance is being valued at $4.75 billion. David Ellison will serve as New Paramount's CEO, while Jeff Shell will serve as president. Redstone will exit Paramount's board of directors and Paramount co-CEO Chris McCarthy will exit the company following the deal's closing. The company's stock will also begin trading on the Nasdaq under the ticker symbol PSKY. Shares of Paramount closed down 1.58% at $13.05 apiece on Friday. The stock is up 13.8% in the past year and 23% year to date. As of the end of Friday's trading session, Paramount has a market capitalization of $9.19 billion. The post Larry Ellison to Hold 35.5% of Family's Voting Rights in New Paramount, National Amusements After Skydance Merger Closes appeared first on TheWrap. Sign in to access your portfolio
